Skip to main content
. 2024 Oct 31;12(11):1241. doi: 10.3390/vaccines12111241

Figure 3.

Figure 3

Mucosal antibody responses against wild-type SARS-CoV-2 (WT) and omicron subvariants induced by XBB.1.5 mRNA vaccines. (a) Saliva levels of anti-RBD IgG before (pre) and two to four weeks after (post) vaccination. (b) Saliva levels of anti-RBD IgA before (pre) and two to four weeks after (post) vaccination. Statistical analyses are based on exact Wilcoxon signed-rank tests.